NIP
EVFM

Nicholas Investment Partners’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Nicholas Investment Partners’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,311
Closed -$969K – 335
2015
Q1 		$969K Sell
1,311
-25
-2% -$16K 0.06% 292
2014
Q4 		$899K Buy
+1,336
New +$1.01M 0.06% 288

Other funds holding EVFM

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Nicholas Investment Partners's EVFM Position: Q2 2015 in Review

Nicholas Investment Partners sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2015, closing a stake of 1,311 shares — an estimated $969K sold.

Nicholas Investment Partners first reported a position in EVFM in Q4 2014 and held it in 2 quarters. The position peaked at $969K in Q1 2015. 24 funds tracked by Wall St. Rank hold EVFM as of Q2 2015.

  • Nicholas Investment Partners reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Nicholas Investment Partners sold 1,311 Evofem Biosciences, Inc. Common Stock shares in Q2 2015, an estimated $969K.
  • Nicholas Investment Partners first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2014 and held it in 2 quarters.
  • Nicholas Investment Partners's Evofem Biosciences, Inc. Common Stock position peaked at $969K in Q1 2015.
  • 24 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2015.

Based on Nicholas Investment Partners's 13F filing for Q2 2015, filed 17 Aug 2015.